Translating the lessons from gene therapy to the development of regenerative medicine

Molecular Therapy

Volumn 19, Issue 3, 2011, Pages 439-441

  Porteus, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

CELL DIFFERENTIATION; CELL LINE; CELL REGENERATION; CELL TRANSFORMATION; CELL TYPE; DNA MODIFICATION; DRUG RESEARCH; EMBRYONIC STEM CELL; ETHNIC DIFFERENCE; GENE THERAPY; GENETIC VARIABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; MEDICAL RESEARCH; NOTE; PATIENT SAFETY; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REGENERATIVE MEDICINE; SOMATIC CELL; STEM CELL TRANSPLANTATION; TISSUE REGENERATION;

EID: 79952119224     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.14     Document Type: Note

References (13)

1. Takahashi, K and Yamanaka, S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fbroblast cultures by defned factors. Cell 126: 663-676. (Pubitemid 44233629)
2. Hanna, JH, Saha, K and Jaenisch, R (2010). Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 143: 508-525.
3. Stadtfeld, M and Hochedlinger, K (2010). Induced pluripotency: history, mechanisms, and applications. Genes Dev 24: 2239-2263.
4. Hanna, J, Wernig, M, Markoulaki, S, Sun, CW, Meissner, A, Cassady, JP et al. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318: 1920-1923.
5. Zou, J, Maeder, ML, Mali, P, Pruett-Miller, SM, Thibodeau-Beganny, S, Chou, BK et al. (2009). Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5: 97-110.
6. Hockemeyer, D, Soldner, F, Beard, C, Gao, Q, Mitalipova, M, DeKelver, RC et al. (2009). Effcient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-fnger nucleases. Nat Biotechnol 27: 851-857.
7. Papapetrou, EP, Lee, G, Malani, N, Setty, M, Riviere, I, Tirunagari, LM et al. (2011). Genomic safe harbors permit high b-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 29: 73-78.
8. Barrett, AJ and Melenhorst, JJ (2011). Is human cell therapy research caught in a mousetrap? Mol Ther 19: 224-227.
9. Shepherd, BE, Kiem, HP, Lansdorp, PM, Dunbar, CE, Aubert, G, LaRochelle, A et al. (2007). Hematopoi-etic stem-cell behavior in nonhuman primates. Blood 110: 1806-1813. (Pubitemid 47443891)
10. Fischer, A, Hacein-Bey-Abina, S and Cavazzana-Cal-vo, M (2010). 20 years of gene therapy for SCID. Nat Immunol 11: 457-460.
11. Mayshar, Y, Ben-David, U, Lavon, N, Biancotti, JC, Yakir, B, Clark, AT et al. (2010). Identifcation and classifcation of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7: 521-531.
12. Laurent, LC, Ulitsky, I, Slavin, I, Tran, H, Schork, A, Morey, R et al. (2011). Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8: 106-118.
13. Prockop, DJ (2010). Defning the probability that a cell therapy will produce a malignancy. Mol Ther 18: 1249-1250.